Society of Gynecologic Oncology Annual Meeting on Women's Cancer (SGO 20/20)

Olaparib-bevacizumab PFS benefit in ovarian cancer greatest following upfront surgery

Roshini Claire Anthony, 20200520140002

The combination of olaparib and bevacizumab as maintenance therapy for advanced ovarian cancer appears to confer the greatest progression-free survival (PFS) benefit in women without residual macroscopic disease following upfront cytoreductive surgery, according to an analysis of the phase III PAOLA-1* trial.

Subgroup findings boost benefit of niraparib in newly-diagnosed ovarian cancer

Audrey Abella, 20200514120816

The PARP* inhibitor niraparib improves progression-free survival (PFS) and is well-tolerated in women with newly diagnosed advanced ovarian cancer (OCa) after a response to first-line (1L) platinum-based chemotherapy (CT), subgroup results of the phase III PRIMA/ENGOT-OV26/GOG-3012 trial have shown.

Trametinib improves PFS in low-grade serous ovarian or peritoneal cancer

Elaine Soliven, 20200512085319

Treatment with trametinib, an MEK inhibitor, significantly improves progression-free survival (PFS) in patients with recurrent low-grade serous ovarian or peritoneal carcinoma (LGSOC) compared with standard of care (SOC), according to a study presented at SGO 20/20.

Adding trastuzumab to chemo ups survival in HER2+ uterine serous carcinoma

Adding trastuzumab to chemo improves survival in HER2+ uterine serous carcinoma

Pearl Toh, 20200511190000

Adding trastuzumab to a chemotherapy backbone of carboplatin and paclitaxel led to sustained survival benefit in patients with recurrent/advanced, HER2-positive uterine serous carcinoma compared with chemotherapy alone, according to an updated survival analysis presented at SGO 2020 Meeting.

Veliparib continues to show positive signals in ovarian cancer

Audrey Abella, 20200508100000

Subgroup analyses of the VELIA* trial showed that the concomitant administration of the poly(adenosine diphosphate-ribose) polymerase inhibitor veliparib with an induction chemotherapy (CT) regimen comprising carboplatin and paclitaxel (CP) generated antitumour activity and favourable safety in women with high-grade serous ovarian cancer.

Frontline maintenance immunotherapy ups RFS in ovarian cancer

Pearl Toh, 20200430190000

Frontline maintenance treatment with a DNA engineered autologous tumour cell (EATC) immunotherapy yields relapse-free survival (RFS) benefit in patients with advanced epithelial ovarian cancer, particularly in those with wild-type BRCA1/2 status, according to the VITAL* study presented at the 2020 SGO Annual Meeting.

Increased osteoporosis risk in young, gynae cancer survivors

Roshini Claire Anthony, 20200430140003

Young gynaecological cancer survivors have an increased risk of bone mineral density (BMD) reductions and osteoporosis, according to a study scheduled for presentation at SGO 20/20.

Adjuvant HPV vaccine could reduce CIN2+ recurrence risk

Roshini Claire Anthony, 20200427140002

Receipt of an adjuvant human papillomavirus (HPV) vaccine following surgical excision could reduce the risk of cervical intraepithelial neoplasia (CIN2+) recurrence, according to a systematic review and meta-analysis submitted for presentation at SGO 20/20.